EP0959880A1 - Formulation pharmaceutique - Google Patents

Formulation pharmaceutique

Info

Publication number
EP0959880A1
EP0959880A1 EP97913126A EP97913126A EP0959880A1 EP 0959880 A1 EP0959880 A1 EP 0959880A1 EP 97913126 A EP97913126 A EP 97913126A EP 97913126 A EP97913126 A EP 97913126A EP 0959880 A1 EP0959880 A1 EP 0959880A1
Authority
EP
European Patent Office
Prior art keywords
formulation according
formula
compound
formulation
levormeloxifene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97913126A
Other languages
German (de)
English (en)
Inventor
Stella Rudkaer Rasmussen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of EP0959880A1 publication Critical patent/EP0959880A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Definitions

  • Centchroman has also been investigated as an anti-cancer agent for treatment of advanced breast cancer (Misra ej aL, Int J Cancer 43 (1989), 781 - 783. Recently, centchroman as a racemate has been found as a potent cholesterol lowering pharmaceutical agent expressed by a significant decrease of the serum concentrations (S.D. Bain ei aL, J Min Bon Res 9 (1994), S 394).
  • hydrophilic binder represents binders commonly used in the formulation of pharmaceuticals, such as polyvinylpyrrolidone, copolyvidone (cross- linked polyvinylpyrrolidone), polyethylene glycol, sucrose, dextrose, corn syrup, polysaccharides (including acacia, tragacanth, guar, and alginates), gelatin, and cellulose derivatives (including hydroxypropyl methylcellulose, hydroxypropyl cellulose, and sodium carboxymethylcellulose).
  • pharmaceuticals such as polyvinylpyrrolidone, copolyvidone (cross- linked polyvinylpyrrolidone), polyethylene glycol, sucrose, dextrose, corn syrup, polysaccharides (including acacia, tragacanth, guar, and alginates), gelatin, and cellulose derivatives (including hydroxypropyl methylcellulose, hydroxypropyl cellulose, and sodium carboxymethylcellulose).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une formulation pharmaceutique destinée à une administration par voie orale, laquelle comprend un composé de la formule (I) dans laquelle R représente alkyle C1-6 ou un sel pharmaceutiquement acceptable dudit composé, en combinaison avec un liant hydrophile et un diluant hydrosoluble.
EP97913126A 1996-11-28 1997-11-26 Formulation pharmaceutique Withdrawn EP0959880A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK135996 1996-11-28
DK135996 1996-11-28
DK126597 1997-11-07
DK126597 1997-11-07
PCT/DK1997/000543 WO1998023270A1 (fr) 1996-11-28 1997-11-26 Formulation pharmaceutique

Publications (1)

Publication Number Publication Date
EP0959880A1 true EP0959880A1 (fr) 1999-12-01

Family

ID=26065492

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97913126A Withdrawn EP0959880A1 (fr) 1996-11-28 1997-11-26 Formulation pharmaceutique

Country Status (4)

Country Link
EP (1) EP0959880A1 (fr)
JP (1) JP2001504502A (fr)
AU (1) AU5049098A (fr)
WO (1) WO1998023270A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA989763B (en) * 1997-11-07 1999-05-07 Novo Nordisk As Pharmaceutical composition comprising levormeloxifene in low dose
EA004872B1 (ru) * 1999-08-03 2004-08-26 ЛИЛЛИ АЙКОС эЛ-эЛ-Си β-КАРБОЛИНОВЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447622A (en) * 1981-09-22 1984-05-08 Council Of Scientific And Industrial Research Rafi Marg Preparation of l- and d-isomers of dl-3,4-trans-2,2-disubstituted-3,4-diarylchromans and derivatives thereof
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
US5563133A (en) * 1995-02-21 1996-10-08 Eli Lilly And Company Hexamethyleneiminyl tachykinin receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9823270A1 *

Also Published As

Publication number Publication date
WO1998023270A1 (fr) 1998-06-04
JP2001504502A (ja) 2001-04-03
AU5049098A (en) 1998-06-22

Similar Documents

Publication Publication Date Title
EP0670162B1 (fr) Formulation pharmaceutique contenant le raloxifère, un agent surfactif et un diluant hydrosoluble
EP0744946B1 (fr) Compositions contenant du nebivolol micronise
US20050096365A1 (en) Pharmaceutical compositions with synchronized solubilizer release
JP2013209419A (ja) 酢酸バゼドキシフェン製剤
WO2003082805A1 (fr) Sels de venlafaxine faiblement solubles dans l'eau
US5977158A (en) Pharmaceutical formulations comprising levormeloxifene compounds
WO2000004880A1 (fr) Technique de granulation humide pour la preparation d'une formulation pharmaceutique stable
US6525084B2 (en) Stable pharmaceutical formulation
WO2005120517A1 (fr) Preparation de suspension liquide stable comprenant des steroides synthetiques et leur procede de production
JP2000506508A (ja) 良性前立腺肥大の治療又は予防のための医薬組成物の製造のための３，４―ジフェニルクロマンの使用
AU1367297A (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical comp osition for the treatment or prophylaxis of menopausal symptoms
US20110196032A1 (en) Pharmaceutical Dosage Form of an Antidepressant
WO2008104880A2 (fr) Formes posologiques solides stables d'un antidépresseur
EP0959880A1 (fr) Formulation pharmaceutique
JPH1192369A (ja) 医薬品調製物、その製造方法及びシランセトロンの安定化のための酸性添加剤の使用
EP2301528B1 (fr) Utilisation du FTS pour le traitement de troubles malins
US20110217369A1 (en) Fenofibrate compositions
TW202444365A (zh) 改良之卡博替尼組合物及其使用方法
US5886021A (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for vasodilatory treatment or prophylaxis
WO1999024031A1 (fr) Composition pharmaceutique comprenant de faibles doses de 3,4-diarylchromannes
AU2018419112B2 (en) Instant release pharmaceutical preparation of anticoagulant and preparation method therefor
EP1560568B1 (fr) Compositions pharmaceutiques a liberation controlee contenant de l'alginate de sodium et de l'alginate de sodium et calcium
CN112220765A (zh) 一种含有辛伐他汀的口服制剂及其制备方法
EP1716848B1 (fr) Composition pharmaceutique solide contenant une forme crystalline de piperidine substituée en positions 1,4
JP7150862B2 (ja) アミノピラン誘導体の組成物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990628

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 19990628;LT PAYMENT 19990628;LV PAYMENT 19990628;MK PAYMENT 19990628;RO PAYMENT 19990628;SI PAYMENT 19990628

17Q First examination report despatched

Effective date: 20010914

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040330